Aduhelm Shockwaves Will Reverberate Across Industry
• By Daniel Chancellor
Generate a summary of this article
Listen to this article
The butterfly effect is an elegant analogy to describe the seemingly unpredictable and far-reaching implications of a relatively small and inconsequential event. The FDA’s approval of Aduhelm is not so much a butterfly gently flapping its wings, but rather a sonic boom emanating from a jet engine. Most immediately, it provides a new therapeutic option for millions of patients in dire need of hope, vindicating Biogen’s faith with a revenue stream running into many billions of dollars. Longer-term the reverberations may be felt across the entire industry, throwing into question the evidentiary requirement for drug development.
• Source: Alamy
The accelerated approval of Aduhelm (aducanumab) creates a momentous opportunity for Biogen, Inc., one that has long been sought after by a range of big pharmas with larger R&D budgets. Companies like Johnson & Johnson, Pfizer Inc., Eli Lilly and Company and Roche Holding AG have attempted to produce the first new drug for Alzheimer’s disease since memantine in 2003, coming up short and creating a discard pile containing almost 200 failed or suspended programs.
For Biogen, success equals access to the millions of patients currently living with the various stages of Alzheimer’s disease in...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
Instead, the new study found children with more severe attention and hyperactivity issues or other mental health conditions such as anxiety were more likely to be medicated for ADHD.
Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)
